JP2021529531A5 - - Google Patents
Info
- Publication number
- JP2021529531A5 JP2021529531A5 JP2020573299A JP2020573299A JP2021529531A5 JP 2021529531 A5 JP2021529531 A5 JP 2021529531A5 JP 2020573299 A JP2020573299 A JP 2020573299A JP 2020573299 A JP2020573299 A JP 2020573299A JP 2021529531 A5 JP2021529531 A5 JP 2021529531A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- antibody
- recombinant
- herpesvirus
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024055149A JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
| JP2025156650A JP2025186440A (ja) | 2018-06-29 | 2025-09-22 | 抗体送達のための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692514P | 2018-06-29 | 2018-06-29 | |
| US62/692,514 | 2018-06-29 | ||
| US201862713066P | 2018-08-01 | 2018-08-01 | |
| US62/713,066 | 2018-08-01 | ||
| PCT/US2019/039939 WO2020006486A1 (en) | 2018-06-29 | 2019-06-28 | Compositions and methods for antibody delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024055149A Division JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529531A JP2021529531A (ja) | 2021-11-04 |
| JP2021529531A5 true JP2021529531A5 (https=) | 2022-06-30 |
Family
ID=68985203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573299A Pending JP2021529531A (ja) | 2018-06-29 | 2019-06-28 | 抗体送達のための組成物及び方法 |
| JP2024055149A Active JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
| JP2025156650A Pending JP2025186440A (ja) | 2018-06-29 | 2025-09-22 | 抗体送達のための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024055149A Active JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
| JP2025156650A Pending JP2025186440A (ja) | 2018-06-29 | 2025-09-22 | 抗体送達のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210261649A1 (https=) |
| EP (1) | EP3866924A4 (https=) |
| JP (3) | JP2021529531A (https=) |
| AU (1) | AU2019292580B2 (https=) |
| CA (1) | CA3103374A1 (https=) |
| WO (1) | WO2020006486A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| RS60410B1 (sr) | 2016-04-08 | 2020-07-31 | Krystal Biotech Inc | Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| US10786438B2 (en) | 2018-04-27 | 2020-09-29 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| EP3921334A1 (en) | 2019-02-08 | 2021-12-15 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2023547026A (ja) * | 2020-09-10 | 2023-11-09 | バスキュラー バイオジェニックス リミテッド | 運動精子ドメイン含有タンパク質２抗体およびその使用法 |
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| BR112023020209A2 (pt) | 2021-04-02 | 2023-12-19 | Krystal Biotech Inc | Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| TW202330598A (zh) * | 2021-06-30 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｂａｆｆ和ｉｌ－１２／２３的抗原結合分子及用途 |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| EP4413046A4 (en) * | 2021-10-05 | 2025-11-26 | Univ Texas | PROCESSES AND COMPOSITIONS COMPRISING B7-H3 BONDING POLYPEPTIDES |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| WO2023224980A1 (en) * | 2022-05-17 | 2023-11-23 | The Uab Research Foundation | Methods and compositions for treating or preventing inflammatory skin disorders |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| CN119816595A (zh) * | 2022-06-30 | 2025-04-11 | 隆萨销售股份有限公司 | 可编辑细胞系 |
| WO2024182737A1 (en) * | 2023-03-01 | 2024-09-06 | The Brigham And Women’S Hospital, Inc. | Oncolytic viruses to treat brain cancer |
| CN116790615B (zh) * | 2023-07-11 | 2024-11-22 | 康霖生物科技（杭州）有限公司 | 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610287B1 (en) * | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| US5658724A (en) * | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
| US6261552B1 (en) * | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
| GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| PL3718564T3 (pl) * | 2003-12-23 | 2024-03-18 | Genentech, Inc. | Nowe przeciwciała anty-IL 13 i ich zastosowania |
| KR20080073293A (ko) * | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| NZ580378A (en) * | 2007-03-30 | 2012-11-30 | Abbott Lab | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells |
| NO2700405T3 (https=) * | 2008-05-29 | 2018-09-01 | ||
| WO2016183312A1 (en) * | 2015-05-13 | 2016-11-17 | Sanofi Pasteur Biologics, Llc | Icp0-mediated enhanced expression system |
| BR112018012180A2 (pt) * | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| US10612005B2 (en) * | 2016-01-08 | 2020-04-07 | Replimune Limited | Modified oncolytic virus |
| RS60410B1 (sr) * | 2016-04-08 | 2020-07-31 | Krystal Biotech Inc | Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože |
-
2019
- 2019-06-28 CA CA3103374A patent/CA3103374A1/en active Pending
- 2019-06-28 AU AU2019292580A patent/AU2019292580B2/en active Active
- 2019-06-28 JP JP2020573299A patent/JP2021529531A/ja active Pending
- 2019-06-28 WO PCT/US2019/039939 patent/WO2020006486A1/en not_active Ceased
- 2019-06-28 EP EP19826446.7A patent/EP3866924A4/en active Pending
- 2019-06-28 US US17/255,383 patent/US20210261649A1/en active Pending
-
2024
- 2024-03-29 JP JP2024055149A patent/JP7749055B2/ja active Active
-
2025
- 2025-09-22 JP JP2025156650A patent/JP2025186440A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529531A5 (https=) | ||
| US11993663B2 (en) | Low-viscosity antigen binding proteins and methods of making them | |
| AU2019292580B2 (en) | Compositions and methods for antibody delivery | |
| JP6961486B2 (ja) | システインプロテアーゼ | |
| KR102524594B1 (ko) | 시스테인 프로테아제 | |
| AU2011219715B2 (en) | Stable antibody containing compositions | |
| CN114671952A (zh) | 具有改善的结合、功能和安全性特征的抗cd154抗体及其在人免疫治疗中的用途 | |
| US20250230186A1 (en) | Stabilised Protein Solutions | |
| JP2024532726A5 (https=) | ||
| AU2019257683A1 (en) | Treatment of atopic dermatitis | |
| JP2023535842A5 (https=) | ||
| EP3958903A1 (en) | Antibody formulation | |
| US10745463B2 (en) | Hyper-glycosylated antibodies with selective Fc receptor binding | |
| CA3175685A1 (en) | Auto-injector assembly | |
| WO2020176730A1 (en) | Antibody formulation | |
| EA043899B1 (ru) | Антигенсвязывающие белки, характеризующиеся низкой вязкостью, и способы их получения | |
| HK1240619A1 (en) | Cysteine protease |